Druggability Assessment for Selected Serine Proteases in a Pharmaceutical Industry Setting

ChemMedChem. 2020 Nov 4;15(21):2010-2018. doi: 10.1002/cmdc.202000425. Epub 2020 Sep 21.

Abstract

Target druggability assessment is an integral part of the early target characterization and selection process in pharmaceutical industry. Here, we investigate a set of five different serine proteases from the blood coagulation cascade. The aim of this study is twofold. Firstly, leveraging the wealth of available in-house high-throughput screening (HTS) data, we analyze HTS hit rates and discuss their predictive value for the development of small molecule (SMOL) candidates. Purely structure-activity relationship (SAR) based druggability ratings are compared with computational protein-structure based druggability assessments. Secondly, we evaluate the impact of using conformational ensembles from molecular dynamics (MD) simulations instead of single static crystal structures as basis for computational druggability assessments. Based on this study, we recommend incorporating molecular dynamics routinely into the early target characterization process, especially if only a single X-ray structure is available.

Keywords: HTS; druggability; molecular dynamics simulation; serine proteases.

MeSH terms

  • Drug Industry*
  • High-Throughput Screening Assays
  • Humans
  • Molecular Dynamics Simulation
  • Serine Proteases / metabolism*
  • Serine Proteinase Inhibitors / chemistry
  • Serine Proteinase Inhibitors / pharmacology*
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology*
  • Structure-Activity Relationship

Substances

  • Serine Proteinase Inhibitors
  • Small Molecule Libraries
  • Serine Proteases